semaglutide cardiovascular trial news outcomes today 2025 Oral Reduces Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized SELECT Trial – Long-term kidney outcomes of semaglutide

It is the first triple-hormone-receptor agonist to reach advanced clinical trials, activating three distinct metabolic pathways that individually would each justify their own drug development program

Nr man vurderer en udbyder, er brugeroplevelsen i fokus: indlsningstider, intuitive menuer og tydelige knapper til ind- og udbetaling betyder meget i hverdagen

Using animal models, the researchers found that GLP-1 drugs improve blood flow to the heart after a heart attack by activating potassium channels, which relax pericytes

Switching medications may not be appropriate for everyone

GLP-1 receptor agonist for weight loss and fertility: social media and online perception versus evidence-based medicine